Want to see IN:CAPLIPOINT full AI Analyst Report?

Caplin Point Laboratories Limited (CAPLIPOINT) Price & Analysis

4 Followers

CAPLIPOINT Stock Chart & Stats

₹1845.95

-₹76.70(-2.97%)

At close: Jan 09 4:00 PM EST

₹1845.95

-₹76.70(-2.97%)

Day’s Range― - ―

52-Week Range₹1,502.45 - ₹2,990.60

Previous CloseN/A

Volume128.91K

Average Volume (3M)10.77K

Market Cap

₹168.91B

Enterprise Value₹105.93B

Total Cash (Recent Filing)₹10.07B

Total Debt (Recent Filing)₹46.10M

Price to Earnings (P/E)25.4

Beta1.36

Next Earnings

Nov 05, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.36%

Share Statistics

EPS (TTM)84.36

Shares Outstanding76,011,696

10 Day Avg. Volume9,353

30 Day Avg. Volume10,773

Financial Highlights & Ratios

PEG Ratio0.91

Price to Book (P/B)3.19

Price to Sales (P/S)5.23

P/FCF Ratio33.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)97

Revenue Forecast (FY)₹25.01B

Bulls Say, Bears Say

Bulls Say

Consistent Revenue GrowthConsistent revenue growth across the periods indicates durable demand for the company’s products and effective commercial execution. Continued top-line expansion can support operating leverage, fund portfolio development, and reinforce Caplin Point’s position in its target generic pharmaceutical markets.

Strong ProfitabilitySustained gross and net profitability demonstrates that Caplin Point captures meaningful value from its formulation manufacturing and distribution model. Healthy margins provide resilience in competitive generic markets and create internal capacity to support launches, registrations, and future business expansion.

Conservative Balance SheetVery low leverage limits financial risk and gives Caplin Point substantial flexibility to fund growth, absorb operational variability, or pursue opportunities without heavy dependence on borrowing. Expanding equity and assets also indicate balance-sheet compounding supported by retained earnings.

Bears Say

Uneven Free-Cash-Flow ConversionAlthough cash generation is positive and improving, inconsistent free-cash-flow conversion means reported earnings do not always translate into deployable cash at the same rate. Periodic working-capital or investment swings could reduce flexibility for reinvestment, distributions, or expansion.

Recent Margin CompressionRecent gross-margin compression and uneven operating profitability indicate that earnings expansion may not consistently keep pace with revenue growth. If this pattern persists, it could limit operating leverage and make future profit growth more dependent on continued volume and execution.

Potential ROE ModerationStrong historical returns on equity are a clear advantage, but the stated possibility of moderation is a structural consideration as the balance sheet expands. If retained earnings increase faster than profits, capital efficiency could gradually decline even while absolute earnings continue to grow.

Caplin Point Laboratories Limited News

Caplin Steriles Wins USFDA Nod for Calcium Gluconate Injection, Expands U.S. Injectables Push

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) just unveiled an update. Caplin Steriles, the sterile injectables arm of...

6M ago

Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has shared an update. Caplin Point Laboratories, through its subsidiaries Caplin...

10M ago

Caplin Steriles Secures USFDA Approval for Acetaminophen Injection

The latest update is out from Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ). Caplin Steriles Limited, a subsidiary...

11M ago

Caplin Point Laboratories Announces Financial Results and New Appointments

An announcement from Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) is now available. Caplin Point Laboratories Limited announced...

12M ago

Caplin Point Laboratories Announces Trading Window Closure

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) just unveiled an announcement. Caplin Point Laboratories Limited announced the closure...

1y ago

Caplin Point Laboratories Sets Record Date for Dividend Ahead of AGM

Caplin Point Laboratories Limited ( ($IN:CAPLIPOINT) ) has provided an announcement. Caplin Point Laboratories Limited has announced the...

1y ago

CAPLIPOINT FAQ

What was Caplin Point Laboratories Limited’s price range in the past 12 months?

Caplin Point Laboratories Limited lowest stock price was ₹1502.45 and its highest was ₹2990.60 in the past 12 months.

What is Caplin Point Laboratories Limited’s market cap?

Caplin Point Laboratories Limited’s market cap is ₹168.91B.

When is Caplin Point Laboratories Limited’s upcoming earnings report date?

Caplin Point Laboratories Limited’s upcoming earnings report date is Nov 05, 2026 which is in 12 days.

How were Caplin Point Laboratories Limited’s earnings last quarter?

Caplin Point Laboratories Limited released its earnings results on Aug 12, 2026. The company reported ₹23.3 earnings per share for the quarter.

Is Caplin Point Laboratories Limited overvalued?

According to Wall Street analysts Caplin Point Laboratories Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Caplin Point Laboratories Limited pay dividends?

Caplin Point Laboratories Limited pays a Semiannually dividend of ₹4 which represents an annual dividend yield of 0.36%. See more information on Caplin Point Laboratories Limited dividends here

What is Caplin Point Laboratories Limited’s EPS estimate?

Caplin Point Laboratories Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Caplin Point Laboratories Limited have?

Caplin Point Laboratories Limited has 76,011,696 shares outstanding.

What happened to Caplin Point Laboratories Limited’s price movement after its last earnings report?

Caplin Point Laboratories Limited reported an EPS of ₹23.3 in its last earnings report. Following the earnings report the stock price went down -5.676%.

Which hedge fund is a major shareholder of Caplin Point Laboratories Limited?

Currently, no hedge funds are holding shares in IN:CAPLIPOINT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive product portfolio encompasses a broad spectrum of pharmaceutical dosage forms, including various types of injections (liquid, lyophilized, IV infusions, powder for injection), oral preparations (tablets, liquid orals, capsules, softgel capsules, dry syrups), specialized applications (ophthalmic products, suppositories and ovules), and topical treatments (topicals, dermo cosmetics, inhalers). Beyond manufacturing, the company also manages an e-commerce platform named QueTenX. Established in 1990, Caplin Point Laboratories maintains its headquarters in Chennai, India.